Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study DOI Creative Commons
Janet L. Kwiatkowski, Mona Hamdy, Amal El‐Beshlawy

et al.

Blood Advances, Journal Year: 2021, Volume and Issue: 6(4), P. 1243 - 1254

Published: Nov. 30, 2021

Abstract Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The chelator deferiprone is frequently used in individuals thalassemia syndromes, but data patients SCD are limited. This open-label study assessed the efficacy and safety of receiving transfusion A total 228 (mean age: 16.9 [range, 3-59] years; 46.9% female) were randomized to receive either oral (n = 152) subcutaneous deferoxamine 76). primary endpoint was change from baseline at 12 months liver concentration (LIC), by R2* magnetic resonance imaging (MRI). least squares mean (standard error) LIC −4.04 (0.48) mg/g dry weight for vs −4.45 (0.57) deferoxamine, noninferiority demonstrated analysis covariance (least difference 0.40 [0.56]; 96.01% confidence interval, −0.76 1.57). Noninferiority also shown both cardiac T2* MRI serum ferritin. Rates overall adverse events (AEs), treatment-related AEs, serious AEs leading withdrawal did not differ significantly between groups. related treatment included abdominal pain (17.1% patients), vomiting (14.5%), pyrexia (9.2%), increased alanine transferase (9.2%) aspartate levels neutropenia (2.6%), agranulocytosis (0.7%). profiles acceptable consistent those seen transfusion-dependent thalassemia. trial registered www://clinicaltrials.gov as #NCT02041299.

Language: Английский

Teucrium polium (L.): Phytochemical Screening and Biological Activities at Different Phenological Stages DOI Creative Commons
Majid Sharifi‐Rad, Paweł Pohl, Francesco Epifano

et al.

Molecules, Journal Year: 2022, Volume and Issue: 27(5), P. 1561 - 1561

Published: Feb. 25, 2022

The aim of the present study was to investigate changes in content phytochemical compounds and vitro antioxidant, antibacterial, anti-inflammatory activities Teucrium polium L. aerial parts root methanolic extracts at different phenological stages (vegetative, flowering, seeding). T. were analyzed using gas chromatography–mass spectrometry (GC-MS), their antioxidant properties tested with 2,2-diphenyl-1-picrylhydrazyl (DPPH), nitric oxide (NO), ferrous ions (Fe2+), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) methods. Forty-nine identified majority germacrene D, t-cadinol, β-pinene, carvacrol, bicyclogermacrene, α-pinene, limonene. results show that significantly differ between plant material used terms composition (total phenolic compounds, total flavonoids, alkaloids, saponin contents) bioactivities (antioxidant, anti-inflammatory) (p < 0.05). highest contents phenolics (72.4 ± 2.5 mg gallic equivalent (GAE)/g dry weight), flavonoids (36.2 3.1 quercetin (QE)/g alkaloids (105.7 2.8 atropine (AE)/g saponins (653 6.2 escin (EE)/g as well activities, measured for extract obtained flowering stage. minimum inhibitory concentration (MIC) values varied within 9.4–300 µg/mL, while bactericidal (MBC) 18.75–600 µg/mL. In addition, they more active on Gram-positive bacteria than Gram-negative bacteria. data this work confirm have significant biological activity hence can be pharmaceutical industry, clinical applications, medical research, cosmetic food industries.

Language: Английский

Citations

34
Equine lactoferrin: Antioxidant properties related to divalent metal chelation DOI Creative Commons
Zhanar Narmuratova, Faiez Hentati, Jean‐Michel Girardet

et al.

LWT, Journal Year: 2022, Volume and Issue: 161, P. 113426 - 113426

Published: April 5, 2022

Lactoferrin is a minor whey protein known for its multifunctionalities, particularly rule in regulation of immune system and antimicrobial activities. Although bovine lactoferrin has been extensively studied, very few information exists on from mare's milk. This article studies the antioxidant properties via metal chelation purified Kazakhstan Equine shows free radical-scavenger activity when tested with radical DPPH ABTS reducing capacities testing by FRAP. Moreover, ferrous(II) copper(II) ion-chelating power highlighted chemical colorimetric tests. Finally, newly introduced biophysics switchSENSE® technology allowed to measure real time molecular interactions between equine divalent cations. The order magnitude KD values was tens or so μM four ions tested: Zn2+ (KD = 23.9 ± 4.0 μM), Ca2+ 28.2 4.4 Cu2+ 43.5 5.1 μM) Fe2+ 54.1 8.9 μM). According these results, we can conclude that radical-scavenging mechanism, pro-oxidant metals ability.

Language: Английский

Citations

30
Targeting ferroptosis in the maintenance of mitochondrial homeostasis in the realm of septic cardiomyopathy DOI
Hua Ye,

Huantao Hu,

Xiaoliang Zhou

et al.

Current Opinion in Pharmacology, Journal Year: 2024, Volume and Issue: 74, P. 102430 - 102430

Published: Jan. 21, 2024

Language: Английский

Citations

8
Role of Iron in the Molecular Pathogenesis of Diseases and Therapeutic Opportunities DOI
Usama Abbasi, Srinivas Abbina, Arshdeep Gill

et al.

ACS Chemical Biology, Journal Year: 2021, Volume and Issue: 16(6), P. 945 - 972

Published: June 9, 2021

Iron is an essential mineral that serves as a prosthetic group for variety of proteins involved in vital cellular processes. The iron economy within humans highly conserved there no proper excretion pathway. Therefore, homeostasis evolved to coordinate acquisition, storage, transport, and recycling efficiently. A disturbance this state can result excess burden which ensuing iron-mediated generation reactive oxygen species imparts widespread oxidative damage proteins, lipids, DNA. On the contrary, problems deficiency either due genetic or nutritional causes lead number disorders. chelation strategies have been works since early 1900s, they still remain most viable therapeutic approach mitigate toxic side effects iron. Intense investigations on improving efficacy while being well tolerated accepted by patients particular focus many researchers over past 30 years. Moreover, recent advances our understanding role pathogenesis different diseases (both overload conditions) motivate need develop new therapeutics. We summarized into health disease conditions, chelation, delivery strategies. Information regarding small molecule macromolecular approaches how are employed such primary secondary diseases, cancer, diabetes, neurodegenerative infections, provided.

Language: Английский

Citations

38
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study DOI Creative Commons
Janet L. Kwiatkowski, Mona Hamdy, Amal El‐Beshlawy

et al.

Blood Advances, Journal Year: 2021, Volume and Issue: 6(4), P. 1243 - 1254

Published: Nov. 30, 2021

Abstract Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The chelator deferiprone is frequently used in individuals thalassemia syndromes, but data patients SCD are limited. This open-label study assessed the efficacy and safety of receiving transfusion A total 228 (mean age: 16.9 [range, 3-59] years; 46.9% female) were randomized to receive either oral (n = 152) subcutaneous deferoxamine 76). primary endpoint was change from baseline at 12 months liver concentration (LIC), by R2* magnetic resonance imaging (MRI). least squares mean (standard error) LIC −4.04 (0.48) mg/g dry weight for vs −4.45 (0.57) deferoxamine, noninferiority demonstrated analysis covariance (least difference 0.40 [0.56]; 96.01% confidence interval, −0.76 1.57). Noninferiority also shown both cardiac T2* MRI serum ferritin. Rates overall adverse events (AEs), treatment-related AEs, serious AEs leading withdrawal did not differ significantly between groups. related treatment included abdominal pain (17.1% patients), vomiting (14.5%), pyrexia (9.2%), increased alanine transferase (9.2%) aspartate levels neutropenia (2.6%), agranulocytosis (0.7%). profiles acceptable consistent those seen transfusion-dependent thalassemia. trial registered www://clinicaltrials.gov as #NCT02041299.

Language: Английский

Citations

35